LIGAND PHARMACEUTICALS (LGND) Fundamental Analysis & Valuation
NASDAQ:LGND • US53220K5048
Current stock price
195.48 USD
-8.22 (-4.03%)
At close:
195.48 USD
0 (0%)
After Hours:
This LGND fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. LGND Profitability Analysis
1.1 Basic Checks
- LGND had positive earnings in the past year.
- In the past year LGND had a positive cash flow from operations.
- In multiple years LGND reported negative net income over the last 5 years.
- LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- LGND's Return On Assets of 7.97% is amongst the best of the industry. LGND outperforms 89.12% of its industry peers.
- The Return On Equity of LGND (12.23%) is better than 86.53% of its industry peers.
- With a decent Return On Invested Capital value of 2.45%, LGND is doing good in the industry, outperforming 79.79% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for LGND is significantly below the industry average of 13.06%.
- The 3 year average ROIC (1.82%) for LGND is below the current ROIC(2.45%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 12.23% | ||
| ROIC | 2.45% |
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
1.3 Margins
- Looking at the Profit Margin, with a value of 46.42%, LGND belongs to the top of the industry, outperforming 96.89% of the companies in the same industry.
- With an excellent Operating Margin value of 17.61%, LGND belongs to the best of the industry, outperforming 86.01% of the companies in the same industry.
- LGND's Operating Margin has improved in the last couple of years.
- LGND has a better Gross Margin (94.57%) than 95.85% of its industry peers.
- In the last couple of years the Gross Margin of LGND has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.61% | ||
| PM (TTM) | 46.42% | ||
| GM | 94.57% |
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
2. LGND Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LGND is destroying value.
- The number of shares outstanding for LGND has been increased compared to 1 year ago.
- LGND has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.73 indicates that LGND is not in any danger for bankruptcy at the moment.
- The Altman-Z score of LGND (5.73) is better than 80.83% of its industry peers.
- The Debt to FCF ratio of LGND is 9.12, which is on the high side as it means it would take LGND, 9.12 years of fcf income to pay off all of its debts.
- LGND's Debt to FCF ratio of 9.12 is fine compared to the rest of the industry. LGND outperforms 79.27% of its industry peers.
- A Debt/Equity ratio of 0.44 indicates that LGND is not too dependend on debt financing.
- The Debt to Equity ratio of LGND (0.44) is worse than 60.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 9.12 | ||
| Altman-Z | 5.73 |
ROIC/WACC0.26
WACC9.24%
2.3 Liquidity
- LGND has a Current Ratio of 22.23. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 22.23, LGND belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
- LGND has a Quick Ratio of 21.98. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 21.98, LGND belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.23 | ||
| Quick Ratio | 21.98 |
3. LGND Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 40.81% over the past year.
- LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.06% yearly.
- LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 60.40%.
- Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 7.54% on average per year.
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%
3.2 Future
- LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.98% yearly.
- Based on estimates for the next years, LGND will show a quite strong growth in Revenue. The Revenue will grow by 13.58% on average per year.
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue Next Year10.22%
Revenue Next 2Y14.18%
Revenue Next 3Y13.08%
Revenue Next 5Y13.58%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. LGND Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 24.31, which indicates a rather expensive current valuation of LGND.
- LGND's Price/Earnings ratio is rather cheap when compared to the industry. LGND is cheaper than 80.31% of the companies in the same industry.
- LGND's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.89.
- LGND is valuated rather expensively with a Price/Forward Earnings ratio of 23.02.
- Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 75.65% of the companies are valued more expensively.
- LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.31 | ||
| Fwd PE | 23.02 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 76.17% of the companies are valued more expensively.
- 75.13% of the companies in the same industry are more expensive than LGND, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.7 | ||
| EV/EBITDA | 37.69 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of LGND may justify a higher PE ratio.
PEG (NY)4.33
PEG (5Y)2.02
EPS Next 2Y10.48%
EPS Next 3Y9.34%
5. LGND Dividend Analysis
5.1 Amount
- No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
LGND Fundamentals: All Metrics, Ratios and Statistics
195.48
-8.22 (-4.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners106.63%
Inst Owner Change-42.5%
Ins Owners1.81%
Ins Owner Change2.61%
Market Cap3.90B
Revenue(TTM)268.09M
Net Income(TTM)124.45M
Analysts85.71
Price Target250 (27.89%)
Short Float %7.09%
Short Ratio6.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.08%
Min EPS beat(2)26.84%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)25.53%
Min EPS beat(4)7.61%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)27.71%
EPS beat(12)12
Avg EPS beat(12)54.84%
EPS beat(16)15
Avg EPS beat(16)61.79%
Revenue beat(2)2
Avg Revenue beat(2)25.06%
Min Revenue beat(2)5.23%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)17.85%
Min Revenue beat(4)5.23%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.07%
Revenue beat(12)12
Avg Revenue beat(12)15.78%
Revenue beat(16)14
Avg Revenue beat(16)16.03%
PT rev (1m)0.68%
PT rev (3m)0.68%
EPS NQ rev (1m)-1.81%
EPS NQ rev (3m)-1.81%
EPS NY rev (1m)0.38%
EPS NY rev (3m)0.91%
Revenue NQ rev (1m)-1.6%
Revenue NQ rev (3m)-1.6%
Revenue NY rev (1m)0.41%
Revenue NY rev (3m)0.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.31 | ||
| Fwd PE | 23.02 | ||
| P/S | 14.54 | ||
| P/FCF | 79.7 | ||
| P/OCF | 78.97 | ||
| P/B | 3.83 | ||
| P/tB | 7.9 | ||
| EV/EBITDA | 37.69 |
EPS(TTM)8.04
EY4.11%
EPS(NY)8.49
Fwd EY4.34%
FCF(TTM)2.45
FCFY1.25%
OCF(TTM)2.48
OCFY1.27%
SpS13.44
BVpS51.01
TBVpS24.74
PEG (NY)4.33
PEG (5Y)2.02
Graham Number96.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.97% | ||
| ROE | 12.23% | ||
| ROCE | 3.1% | ||
| ROIC | 2.45% | ||
| ROICexc | 4.72% | ||
| ROICexgc | 14.03% | ||
| OM | 17.61% | ||
| PM (TTM) | 46.42% | ||
| GM | 94.57% | ||
| FCFM | 18.24% |
ROA(3y)4.72%
ROA(5y)2.84%
ROE(3y)6.4%
ROE(5y)4.11%
ROIC(3y)1.82%
ROIC(5y)2.16%
ROICexc(3y)3.31%
ROICexc(5y)3.45%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.31%
ROCE(5y)2.73%
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.34%
ROICexc growth 3Y108.05%
ROICexc growth 5Y42.36%
OM growth 3Y125.81%
OM growth 5Y30.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.97%
GM growth 5Y2.47%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 9.12 | ||
| Debt/EBITDA | 5.51 | ||
| Cap/Depr | 1.34% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 147.04 | ||
| Cash Conversion | 60.96% | ||
| Profit Quality | 39.3% | ||
| Current Ratio | 22.23 | ||
| Quick Ratio | 21.98 | ||
| Altman-Z | 5.73 |
F-Score5
WACC9.24%
ROIC/WACC0.26
Cap/Depr(3y)60.81%
Cap/Depr(5y)46.88%
Cap/Sales(3y)16.73%
Cap/Sales(5y)12.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.81%
EPS 3Y23.39%
EPS 5Y12.06%
EPS Q2Q%59.06%
EPS Next Y5.61%
EPS Next 2Y10.48%
EPS Next 3Y9.34%
EPS Next 5Y12.98%
Revenue 1Y (TTM)60.4%
Revenue growth 3Y10.97%
Revenue growth 5Y7.54%
Sales Q2Q%39.37%
Revenue Next Year10.22%
Revenue Next 2Y14.18%
Revenue Next 3Y13.08%
Revenue Next 5Y13.58%
EBIT growth 1Y108.55%
EBIT growth 3Y150.57%
EBIT growth 5Y40.24%
EBIT Next Year256.46%
EBIT Next 3Y62.3%
EBIT Next 5Y45.87%
FCF growth 1Y-48.64%
FCF growth 3Y-25.86%
FCF growth 5Y-0.48%
OCF growth 1Y-49.14%
OCF growth 3Y-29%
OCF growth 5Y-2%
LIGAND PHARMACEUTICALS / LGND Fundamental Analysis FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 8 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.